JPWO2023017252A5 - - Google Patents

Info

Publication number
JPWO2023017252A5
JPWO2023017252A5 JP2024508382A JP2024508382A JPWO2023017252A5 JP WO2023017252 A5 JPWO2023017252 A5 JP WO2023017252A5 JP 2024508382 A JP2024508382 A JP 2024508382A JP 2024508382 A JP2024508382 A JP 2024508382A JP WO2023017252 A5 JPWO2023017252 A5 JP WO2023017252A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
injection
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024508382A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024530954A (ja
JP2024530954A5 (https=
Publication date
Priority claimed from GBGB2115152.7A external-priority patent/GB202115152D0/en
Priority claimed from GBGB2204211.3A external-priority patent/GB202204211D0/en
Priority claimed from GBGB2204291.5A external-priority patent/GB202204291D0/en
Application filed filed Critical
Priority claimed from PCT/GB2022/052070 external-priority patent/WO2023017252A1/en
Publication of JP2024530954A publication Critical patent/JP2024530954A/ja
Publication of JP2024530954A5 publication Critical patent/JP2024530954A5/ja
Publication of JPWO2023017252A5 publication Critical patent/JPWO2023017252A5/ja
Pending legal-status Critical Current

Links

JP2024508382A 2021-08-10 2022-08-09 アトピー性皮膚炎の処置 Pending JP2024530954A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB202111492 2021-08-10
GB2111492.1 2021-08-10
GBGB2115152.7A GB202115152D0 (en) 2021-10-21 2021-10-21 Treatment of atopic dermatitis
GB2115152.7 2021-10-21
GB2204211.3 2022-03-24
GBGB2204211.3A GB202204211D0 (en) 2022-03-24 2022-03-24 Treatment of atopic dermatitis
GB2204291.5 2022-03-25
GBGB2204291.5A GB202204291D0 (en) 2022-03-25 2022-03-25 Treatment of atopic dermatitis
PCT/GB2022/052070 WO2023017252A1 (en) 2021-08-10 2022-08-09 Treatment of atopic dermatitis

Publications (3)

Publication Number Publication Date
JP2024530954A JP2024530954A (ja) 2024-08-27
JP2024530954A5 JP2024530954A5 (https=) 2025-08-19
JPWO2023017252A5 true JPWO2023017252A5 (https=) 2025-08-19

Family

ID=82942548

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024508382A Pending JP2024530954A (ja) 2021-08-10 2022-08-09 アトピー性皮膚炎の処置

Country Status (11)

Country Link
US (2) US20230235069A1 (https=)
EP (1) EP4384270A1 (https=)
JP (1) JP2024530954A (https=)
KR (1) KR20240043789A (https=)
AR (1) AR126749A1 (https=)
AU (1) AU2022326849A1 (https=)
CA (1) CA3228708A1 (https=)
IL (1) IL310701A (https=)
MX (1) MX2024001877A (https=)
TW (1) TW202330023A (https=)
WO (1) WO2023017252A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260026080A (ko) * 2023-06-20 2026-02-25 키맵 리미티드 면역 매개 질환의 투여 및 치료와 면역 매개 질환과 관련된 바이오마커
WO2025090570A1 (en) * 2023-10-23 2025-05-01 Abcellera Biologics Inc. Anti-ox40l antibodies and methods of use
WO2025233445A1 (en) * 2024-05-08 2025-11-13 Kymab Limited Treatment of head and neck atopic dermatitis
WO2025255353A1 (en) * 2024-06-06 2025-12-11 Apogee Therapeutics, Inc. Dosage and administration of an anti-ox40l antibody

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2426744C2 (ru) * 2005-12-16 2011-08-20 Дженентек, Инк. Антитела к ox40l и способы их применения
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP2513145B1 (en) * 2009-12-14 2018-01-24 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN107074951B (zh) * 2014-08-04 2021-08-03 贝勒研究院 拮抗性抗-ox40l抗体及其使用方法
MX2017011194A (es) 2015-03-03 2018-04-10 Kymab Ltd Anticuerpos, usos y métodos.
US9512229B2 (en) * 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods

Similar Documents

Publication Publication Date Title
US11167004B2 (en) Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
US20250082750A1 (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
CN111526920A (zh) 通过施用il-4r拮抗剂来治疗或预防哮喘的方法
JP2025172841A5 (https=)
AU2017332732B2 (en) Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
EP3793597A1 (en) Methods for treating atopic dermatitis by administering an il-4r inhibitor
EP3713956A1 (en) Treating hidradenitis suppurativa with il-17 antagonists
JP2025102888A (ja) Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
KR20250096792A (ko) Il-4r 길항제를 투여하여 손 및 발 피부염을 치료하기 위한 방법
US20250042985A1 (en) Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp)
JPWO2023017252A5 (https=)
JPWO2021195530A5 (https=)
EP4267184B1 (en) Interleukin 5 binding protein dosage regimen
RU2024105814A (ru) Лечение атопического дерматита
WO2018158741A1 (en) Psoriasis disease modification following long-term treatment with an il-17 antagonist
WO2022136209A1 (en) Interleukin 5 binding protein dosage regimen
KR20260013475A (ko) 루푸스의 치료
KR20220110512A (ko) 인터류킨-17(il-17) 길항제를 사용하여 편평 태선을 치료하는 방법
TW202500184A (zh) 治療潰瘍性結腸炎之方法
CN116635417A (zh) 白介素5结合蛋白给药方案
JPWO2022238479A5 (https=)
TH2001001181A (th) วิธีการสำหรับการบำบัดโรคที่เกี่ยวข้องกับ-tnf